Investor Information

Share Information

Shares of Lonza Group Ltd are listed on the SIX Swiss Exchange and were included in the Swiss Leader Index (SLI) in 2016. Lonza also maintains a secondary listing on the SGX Singapore Exchange. The nominal value of the Lonza Group Ltd share is CHF 1. Lonza's share price closed at the end of 2016 at CHF 176.30, which represents an increase of 8.1% in 2016.

The free float in Lonza Group Ltd registered shares reached 99.76% at year-end, and the average daily trade volume was 161,861 shares in 2016.

Listing and Security Information

Stock Exchange Listing / Trading:

  • SIX Swiss Exchange
  • SGX Singapore Exchange

Common Stock Symbols

  • Bloomberg LONN VX
  • Reuters LONN VX
  • Telekurs LONN
  • SGX O6Z

Security Number

  • Valor 001384101
  • ISIN CH0013841017

Upcoming Financial Events

Date and Time Event
   
25 April 2017, 10:00 am CET Annual General Meeting for the Financial Year 2016
Congress Center Basel, Switzerland
26 April 2017 Q1 2017 Business Update
26 July 2017 Half-Year Report 2017
26 October 2017 Q3 2017 Business Update
24 January 2018 Full-Year Report 2017
4 May 2018, 10:00 am CET Annual General Meeting for the Financial Year 2017
Congress Center Basel, Switzerland

Shareholdings

According to disclosure notifications filed with Lonza, the following shareholders held more than 3% of Lonza's share capital as of 31 December 2016:

Principal Shareholders %
   
BlackRock, Inc., New York, NY (USA) 10.34
Massachusetts Mutual Life Insurance Company, Springfield, MA (USA) 4.51
Norges Bank (the Central Bank of Norway), Oslo (NOR) 3.78

 

Lonza knows of no other shareholder(s) that owned more than 3% of our share capital as of 31 December 2016. To the best of Lonza’s knowledge, the above-mentioned shareholders are not linked by any shareholders’ agreement or similar arrangement with respect to their shareholdings in Lonza or the exercise of shareholders’ rights. For a full review of the individual disclosure notifications made during 2016, please refer to the SIX Swiss Exchange disclosure platform.

Share Price Development 2016

Lonza Share Price

Lonza Share Price Development vs. Swiss Leader Index and the Swiss Market Index (Rebased)

Lonza Share Price vs. SMI

Dividend Payment History (in CHF/Share)

Lonza Dividend Payment

million CHF 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
                     
Sales 2,870 2,937 2,690 2,680 2,692 3,925 3,584 3,640 3,803 4,132
Result from operating activities (EBIT) 408 441 239 374 261 340 253 423 428 486
Net capital invested 3,277 3,768 3,900 3,688 5,667 5,437 4,958 5,224 4,859 5,026
Return on net capital invested (RONOA) in % 14.1 13.8 6.7 10.8 6.9 7.5 5.9 10.3 10.8 12.7
Headcount 6,929 8,462 8,386 8,280 11,001 10,789 9,935 9,809 9,829 10,130

Significant News Releases

The most significant news releases, other than results publications, during the course of 2016 were the following:

Date News Release
   
13 January 2016 Lonza Expands Single-Use Manufacturing Capacity in Slough (UK) Facility to Meet Customer Demand
2 February 2016 Lonza to Build Capabilities for Drug Product Development Services, Enabling One-Stop-Shop Solutions for Customers
8 February 2016 Kodiak Sciences Inc. and Lonza Announce Agreements for the Development and Manufacture of Medicines for the Treatment of Retinal Disease
10 May 2016 Rodolfo Savitzky Appointed as New CFO for Lonza Group to Succeed Toralf Haag, Who Was Appointed as CFO of the Voith Group in Germany
9 June 2016  Lonza and bluebird bio, Inc., Establish a Long-Term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products
30 June 2016 Lonza Acquires Triangle Research Labs, a Hepatocyte Provider Based in North Carolina (USA)
15 August 2016 Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals
12 October 2016 Lonza Prices CHF 250 Million Five-Year Straight Bond with a 0.125% Coupon
13 October 2016 Lonza and Forty Seven, Inc., Announce Strategic Manufacturing Agreement for Immuno-Oncology Therapeutic Antibody Pipeline
27 October 2016 Lonza and Clovis Oncology Sign Strategic Long-Term Manufacturing Agreement to Secure Supply of Rucaparib
2 November 2016 Lonza Holds Grand Opening for State-of-the-Art Drug Product Services Labs
7 December 2016 Lonza to Divest Peptides Business and Operations in Braine-l’Alleud, Belgium, to PolyPeptide
15 December 2016  Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and Consumer Healthcare Industries

For a comprehensive review of the media releases issued during 2016, refer to www.lonza.com/news